Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A+CHP versus CHOP in frontline treatment of CD30-positive mature T-cell lymphomas
2012-002751-42Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Nov 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), non-Hodgkin lymphoma, T-cell and anaplastic large cell lymphoma (ALCL) (2 arms), sponsored by Seagen Inc. Primary endpoint: Progression-free survival per independent review facility (IRF). Started Nov 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)non-Hodgkin lymphoma, T-cellanaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2012-002751-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002751-42.